1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-08-12 am EDT
3861.00 JPY   +2.03%
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Obtains Regulatory Approval for FoundationOne CDx Cancer Genomic Profile to be Used as Companion Diagnostic of Four Drugs for the Treatment of Non-Small Cell Lung Cancer and Malignant Melanoma

06/06/2022 | 08:34am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) on June 2, 2022, for FoundationOne CDx Cancer Genomic Profile to be used as a companion diagnostic (CDx) for non-small cell lung cancer (NSCLC) therapies, a tyrosine kinase inhibitor VIZIMPRO tablets (generic name: dacomitinib hydrate) and a tyrosine kinase inhibitor ALUNBRIG tablets (generic name: brigatinib), as well as for malignant melanoma therapies, a BRAF inhibitor BRAFTOVI capsules (generic name: encorafenib) and a MEK inhibitor MEKTOVI tablets (generic name: binimetinib).

'With a single test, FoundationOne CDx Cancer Genomic Profile can identify genomic alterations of each patient's cancer comprehensively. This enables them to develop treatment plans tailored to the individual patients, realizing advanced personalized healthcare,' said Dr. Osamu Okuda, Chugai's President and CEO. 'We believe this portfolio expansion of companion diagnostics for four molecular-targeted drugs approved in Japan for the treatment of NSCLC and melanoma, will increase its value as a decision support and contribute to improved treatment access for patients with these types of cancer. We aim to further contribute to advancing cancer treatment by pursuing additional companion diagnostic indications.'

As a companion diagnostic, FoundationOne CDx Cancer Genomic Profile will be used to identify patients with activated EGFR alteration positive or ALK fusion gene positive NSCLC who may benefit from dacomitinib hydrate or brigatinib, respectively. It will also be used to identify patients with BRAF alteration positive malignant melanoma who may benefit from encorafenib and binimetinib combination.

As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized oncology care and supporting to patients and healthcare professionals through improving access to comprehensive genomic profiling.

About FoundationOne CDx Cancer Genomic Profile

Developed by Foundation Medicine Inc., FoundationOne CDx Cancer Genomic Profile is a next-generation sequencing based in vitro diagnostic device for the detection of substitutions, insertion and deletion alterations, and copy number alterations in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The program is available as a companion diagnostic for multiple molecular-targeted drugs approved in Japan.

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD 2.03% 3861 Delayed Quote.1.31%
ROCHE HOLDING AG 1.35% 314.3 Delayed Quote.-18.19%
All news about CHUGAI PHARMACEUTICAL CO., LTD
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/10Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
08/10CHUGAI PHARMACEUTICAL : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
08/09Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
08/08Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
08/08CHUGAI PHARMACEUTICAL : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
08/08Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
08/07CHUGAI PHARMACEUTICAL : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
07/27Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
07/26Nikkei inches lower while traders wait on Fed
RE
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 191 B 8 973 M 8 973 M
Net income 2022 347 B 2 616 M 2 616 M
Net cash 2022 518 B 3 904 M 3 904 M
P/E ratio 2022 17,9x
Yield 2022 2,11%
Capitalization 6 225 B 46 887 M 46 887 M
EV / Sales 2022 4,79x
EV / Sales 2023 5,25x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 784,00 JPY
Average target price 4 617,50 JPY
Spread / Average Target 22,0%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD1.31%46 887
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-16.39%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211